BARCELONA, Spain — Use of ravulizumab for long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) offered sustained protection from relapse for at least 3 years, results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results